Ithimba labacwaningi abavela e-Abramson Cancer Center (ACC) e-University of Pennsylvania School of Medicine lithole ukuthi ukuthi isimila siyashisa noma siyabanda kunqunywa ulwazi olufakwe kumangqamuzana omdlavuza ngokwawo. “Hot” tumors are often considered more sensitive to immunotherapy. In a new study published this week in Immunity, the researchers explored the role of “tumor heterogeneity”, namely the ability of tumor cells to move, replicate, metastasize and respond to treatment. These new findings can help oncologists more accurately tailor the unique isisu composition of patients.
UBen Stanger, uprofesa we-gastroenterology kanye ne-cell kanye ne-biology yokuthuthuka e-University of Pennsylvania Perelman School of Medicine, uthe izinga amaseli ama-T adonswa ngalo ngamathumba alawulwa yizakhi zofuzo eziqondene ngqo nesimila. Ukuze kukhule izicubu, kudingeka zigweme ukuhlaselwa amasosha omzimba. Kunezindlela ezimbili: ukukhula zibe izicubu ezibandayo, noma izicubu ezishisayo ezingachitha amaseli we-T, zivikele ngempumelelo amaseli ezinwele ekulimaleni amasosha omzimba esiguli.
In this study, researchers found that whether a tumor is hot or cold determines whether it will respond to immunotherapy. Cold tumor cells produce a compound called CXCL1, which can instruct bone marrow cells to enter the tumor, keep T cells away from the tumor, and ultimately make the immunotherapy insensitive. In contrast, knocking out CXCL1 in cold tumors promotes T cell infiltration and sensitivity to immunotherapy.
Ithimba likhiqize uchungechunge lwemigqa yamaseli elingisa izici zamathumba e-pancreatic, kufaka phakathi izinhlobo zamaseli omzimba aqukethe. Ngokuzayo, le migqa yamangqamuzana esithumba ingasiza ukuqhubeka nokuhlonza nokwandisa ukwelashwa kwama-subtypes athile eziguli ezinezifo ezahlukahlukene zesimila.
